Redosine Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.72 M
- Revenue Growth 149.82%
- Profit Growth 127.35%
- Ebitda 531.08%
- Net Worth 88.35%
- Total Assets 71.48%
About Redosine Pharmaceutical
Redosine Pharmaceutical Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 June 2018 (Six years and seven months 19 days old ). Its registered office is in Singhbhum, Jharkhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.72 M.
Ranjeet Singh and Hemant Das serve as directors at the Company.
Company Details
-
Location
Singhbhum, Jharkhand, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999JH2018PTC011520
-
Company No.
011520
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Jun 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jharkhand
Industry
Who are the key members and board of directors at Redosine Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ranjeet Singh
|
Director | 15-Jun-2018 | Current |
|
Hemant Das
|
Director | 15-Jun-2018 | Current |
Financial Performance of Redosine Pharmaceutical.
Redosine Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 149.82% increase. The company also saw a substantial improvement in profitability, with a 127.35% increase in profit. The company's net worth Soared by an impressive increase of 88.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Redosine Pharmaceutical?
Unlock access to Redosine Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.72 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Feb 2023 | Hdfc Bank Limited | ₹0.72 M | Open |
How Many Employees Work at Redosine Pharmaceutical?
Unlock and access historical data on people associated with Redosine Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Redosine Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Redosine Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
